US-based Rafael Pharmaceuticals has launched a Phase I clinical trial of its drug candidate CPI-613 to be assessed in combination with chemotherapeutics, gemcitabine, and nab-paclitaxel to treat patients with pancreatic cancer.
CPI-613 is being developed as an altered energy metabolism directed (AEMD) drug to target the mitochondrial metabolism of cancer cells for disrupting their altered energy-production pathways.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
To be performed in partnership with Atlantic Health System, the Phase I trial will evaluate the combination therapy in subjects with locally advanced or metastatic pancreatic cancer.
The trial’s primary objective is to determine the maximum tolerated dose of CPI-613 when administered in conjunction with the chemotherapeutics.
Rafael Pharmaceuticals CEO Sanjeev Luther said: “Patients with a low-tolerance for toxicity may not be eligible for the Folfirinox combo.
“We believe that the gemcitabine/nab-paclitaxel regimen has the potential to be a potent treatment with less toxicity.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe secondary objectives of the Phase I trial are safety and clinical activity of the combination, progression-free survival (PFS) and overall survival (OS).
Trial principal investigator Dr Angela Alistar said: “Due to the low toxicity profile of CPI-613 as a single agent, I anticipate good tolerance in combination with the gemcitabine/nab-paclitaxel regimen.”
Previous trial results are reported to have demonstrated the favourable safety and tolerability profile of CPI-613, which is under assessment in various Phase I, I/II and II trials.
CPI-613 obtained orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of acute myeloid leukaemia (AML), pancreatic cancer and myelodysplastic syndromes (MDS).
